Metagenomi, Inc. Common Stock (MGX) vs Nephros, Inc. (NEPH)
A side-by-side comparison of Metagenomi, Inc. Common Stock and Nephros, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
MGX
Metagenomi, Inc. Common Stock
$1.07HealthcareDelayed quote: Oct 6, 2026, 12:54 PM EDT
NEPH
Nephros, Inc.
$3.67HealthcareDelayed quote: Oct 6, 2026, 12:35 PM EDT
Total return — MGX vs NEPH
growth of $100 · dividends reinvested · last 3yMGX -89.9% (-53.4%/yr)NEPH +0.9% (+0.3%/yr)NEPH compounded faster over this window
Log scale — wide-divergence pair
MGX NEPH
MGX vs NEPH: by the numbers
- •MGX is the larger company ($40M vs $40M market cap).
- •NEPH is profitable (8.38% net margin) while MGX runs a net loss (-689.20%).
Metrics side by side
Valuation
| Metric | MGX | NEPH |
|---|---|---|
| P/E ratio | N/A | 23.13 |
| Forward P/E | N/A | 23.43 |
| P/S ratio | 2.96 | 1.92 |
| P/B ratio | 0.36 | 3.33 |
| EV / EBITDA | N/A | 20.41 |
Profitability
| Metric | MGX | NEPH |
|---|---|---|
| Gross margin | 74.29% | 60.31% |
| Operating margin | -380.85% | 7.92% |
| Net margin | -689.20% | 8.38% |
| ROE | -83.03% | 14.51% |
| ROIC | -66.03% | 12.67% |
Growth (annualized)
| Metric | MGX | NEPH |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 16.99% |
| Total return CAGR (5Y) | N/A | -15.93% |
Frequently asked
- Is MGX or NEPH more profitable?
- NEPH runs the higher net margin — MGX at -689.20% versus NEPH at 8.38%.
Go deeper
Dig into the metrics
Nephros P/E ratioMetagenomi, Inc. Common Stock ROENephros ROEMetagenomi, Inc. Common Stock operating marginNephros operating marginMetagenomi, Inc. Common Stock revenue growthNephros revenue growthMetagenomi, Inc. Common Stock free cash flowNephros free cash flow
Metagenomi, Inc. Common Stock & Nephros appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.